Cargando…

At what price do we treat patients with testicular cancer?

Detalles Bibliográficos
Autor principal:	Daugaard, Gedske
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2013
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4041547/ https://www.ncbi.nlm.nih.gov/pubmed/26217142 http://dx.doi.org/10.1016/j.ejcsup.2013.07.045

Ejemplares similares

Prediction of Nephrotoxicity Associated With Cisplatin-Based Chemotherapy in Testicular Cancer Patients
por: Garcia, Sara L, et al.
Publicado: (2020)

Danish translation and pilot testing of the European Organization for Research and Treatment of Cancer QLQ-TC 26 (EORTC QLQ-TC26) questionnaire to assess health-related quality of life in patients with testicular cancer
por: Bager, Louise, et al.
Publicado: (2018)

Predicting Hearing Loss in Testicular Cancer Patients after Cisplatin-Based Chemotherapy
por: Garcia, Sara L., et al.
Publicado: (2023)

The Danish Testicular Cancer database
por: Daugaard, Gedske, et al.
Publicado: (2016)

Evaluation of Circulating miRNA Biomarkers of Testicular Germ Cell Tumors during Therapy and Follow-up―A Copenhagen Experience
por: Mørup, Nina, et al.
Publicado: (2020)

Cancer therapy and risk of congenital malformations in children fathered by men treated for testicular germ-cell cancer: A nationwide register study
por: Al-Jebari, Yahia, et al.
Publicado: (2019)

Understanding the lingering consequences of what we treat and what we do
por: Angus, Derek C
Publicado: (2004)

Cohort Profile: The Danish Testicular Cancer Late Treatment Effects Cohort (DaTeCa-LATE)
por: Kreiberg, Michael, et al.
Publicado: (2018)

A randomized double-blind study of testosterone replacement therapy or placebo in testicular cancer survivors with mild Leydig cell insufficiency (Einstein-intervention)
por: Bandak, Mikkel, et al.
Publicado: (2017)

Association between polymorphisms in the aryl hydrocarbon receptor repressor gene and disseminated testicular germ cell cancer
por: Brokken, Leon J. S., et al.
Publicado: (2013)

Prognostic factors for relapse in patients with clinical stage I testicular cancer: protocol for a Danish nationwide cohort study
por: Wagner, Thomas, et al.
Publicado: (2019)

Progressive Resistance Training and Cancer Testis (PROTRACT) - Efficacy of resistance training on muscle function, morphology and inflammatory profile in testicular cancer patients undergoing chemotherapy: design of a randomized controlled trial
por: Christensen, Jesper F, et al.
Publicado: (2011)

The cancer-obesity connection: what do we know and what can we do?
por: Riboli, Elio
Publicado: (2014)

Febrile Neutropenia and Long-term Risk of Infection Among Patients Treated With Chemotherapy for Malignant Diseases
por: Nordvig, Josefine, et al.
Publicado: (2018)

Luteinizing Hormone Receptor Is Expressed in Testicular Germ Cell Tumors: Possible Implications for Tumor Growth and Prognosis
por: Lorenzen, Mette, et al.
Publicado: (2020)

What Price Are We Willing to Pay for the Dream of Equal Justice?(†)
por: Higgins, Andrew
Publicado: (2021)

Treating lung cancer in patients with interstitial lung disease: what do we know?
por: Graur, Alexander, et al.
Publicado: (2023)

Multimorbidity: What do we know? What should we do?
por: Navickas, Rokas, et al.
Publicado: (2016)

Treating Chronic Pain with SSRIs: What Do We Know?
por: Patetsos, Elias, et al.
Publicado: (2016)

The risk of viral transmission in feed: What do we know, what do we do?
por: Dee, Scott A., et al.
Publicado: (2020)

Quasicrystals: What do we know? What do we want to know? What can we know?
por: Steurer, Walter
Publicado: (2018)

COVID-19 vaccine: what are we doing and what should we do?
por: Candelli, Marcello
Publicado: (2022)

Presbyopia: What We Do Know and What We Do Not Know in 2022
por: Grzybowski, Andrzej, et al.
Publicado: (2023)

Keeping the Journal in the Second Quarter: What Are We Doing and What Will We Do?
por: Altay, Servet
Publicado: (2023)

Particle Physics Outreach: What we are doing and what we could be doing
por: Goldfarb, Steven
Publicado: (2018)

What do we know and when do we know it?
por: Nicholls, Anthony
Publicado: (2008)

Peritoneal carcinosis in male germ cell tumor patients: a registry study compiled by the German Testicular Cancer Study Group (GTCSG)
por: Seidel, Christoph, et al.
Publicado: (2022)

Why we do what we do. A brief analysis of cancer therapies
por: Galmarini, Carlos M.
Publicado: (2020)

Isolated Nocturnal Hypertension: What Do We Know and What Can We Do?
por: Tadic, Marijana, et al.
Publicado: (2020)

Multinational monkeypox outbreak: what do we know and what should we do?
por: Memariani, Mojtaba, et al.
Publicado: (2022)

A Validated Algorithm for Register-Based Identification of Patients with Relapse of Clinical Stage I Testicular Cancer
por: Wagner, Thomas, et al.
Publicado: (2023)

Coffee and digestive cancers—what do we know, and where do we go?
por: Loftfield, Erikka, et al.
Publicado: (2020)

Globalization of spine care: how are we doing and what are we doing?
por: Chapman, Jens
Publicado: (2012)

Treating Postpartum Depression: What Do We Know about Brexanolone?
por: Ali, Muneeza, et al.
Publicado: (2021)

Veteran homelessness in Australia: What do we know? What has been done? What do we need to do?
por: Wallace, Duncan, et al.
Publicado: (2023)

Experiencing mathematics: what do we do, when we do mathematics?
por: Hersh, Reuben
Publicado: (2014)

Do We Mean What We Say?
por: Towner, Ausburn
Publicado: (1885)

Drugs for malaria elimination: what do we have now and what do we need?
por: Shanks, Dennis
Publicado: (2014)

Evolutionary ecology of Chagas disease; what do we know and what do we need?
por: Flores‐Ferrer, Alheli, et al.
Publicado: (2017)

Teleneurorehabilitation in the COVID-19 Era: What Are We Doing Now and What Will We Do Next?
por: Calabrò, Rocco Salvatore
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qvgpkdpvd0idc60613u0aln363